Blood mRNA Panel May Detect Early Pancreatic Cancer
Key Takeaways
- In a single-center case-control diagnostic accuracy pilot, a 56-gene peripheral whole-blood mRNA panel detected 9 of 10 stage 0-I pancreatic ductal adenocarcinoma cases, while CA19-9 detected 1 of 10.
- In the sample, the combined Panregza assay was reported to have 60% sensitivity and 93.3% specificity for early-stage pancreatic ductal adenocarcinoma.
- The analysis included 10 patients with stage 0-I pancreatic cancer and 104 healthy individuals, and the investigators reported detectable whole-blood gene-expression abnormalities despite normal CA19-9 levels.
Pancreatic cancer is difficult to identify early, with stage 0-I disease accounting for 2%-3% of diagnosed cases. Panregza, a blood test that combines peripheral whole-blood gene-expression patterns with CA19-9, had previously been used mainly in advanced pancreatic cancer. The study examined whether blood-based gene-expression changes are detectable when tumor burden is still minimal.
The analyzed cohort comprised 10 patients with stage 0-I pancreatic cancer and 104 healthy individuals, with the early-stage group representing 4% of 253 pancreatic cancer cases in the source background. In that sample, the combined Panregza assay was reported to have 60% sensitivity and 93.3% specificity. The authors further reported that whole-blood gene-expression abnormalities were detectable even when CA19-9 levels were normal, which they interpreted as a signal not dependent on tumor volume.
The background cited by the investigators also noted that 5-year survival at Kanazawa University Hospital has been 100% for stage 0 pancreatic cancer and 74.4% for stage I disease, underscoring why very early detection remains a central challenge. Those institutional survival figures were presented as context rather than outcomes from the diagnostic study itself. The reported finding was that an early-stage blood gene-expression signal was observed in peripheral blood even when CA19-9 levels were normal.
Clinician Questions
How did the 56-gene whole-blood mRNA panel compare with CA19-9 for stage 0-I pancreatic ductal adenocarcinoma detection?
Miyazawa and colleagues reported detection of 9 of 10 stage 0-I pancreatic ductal adenocarcinoma cases with the 56-gene peripheral whole-blood mRNA panel, versus 1 of 10 with CA19-9, in a pilot single-center case-control diagnostic accuracy study.
What population was evaluated in the pilot whole-blood mRNA study for early-stage pancreatic ductal adenocarcinoma?
The investigators analyzed 10 patients with stage 0-I pancreatic cancer and compared them with 104 healthy individuals; the 10 early-stage cases also represented 4% of 253 pancreatic cancer cases in the source background.
What sensitivity and specificity were reported for the combined Panregza test in early-stage pancreatic cancer?
The combined Panregza assay was reported to have 60% sensitivity and 93.3% specificity in the studied sample.
Were whole-blood gene-expression abnormalities reported in stage 0-I pancreatic cancer with normal CA19-9 levels?
The investigators reported detectable whole-blood gene-expression abnormalities even in stage 0-I pancreatic cancer with normal CA19-9 levels, which they interpreted as evidence that the blood signal might not depend on tumor volume.